Wegovy vs Zepbound: Which GLP-1 Weight Loss Drug Wins in 2026?

Zepbound (tirzepatide) produces more average weight loss in head-to-head data — about 20–22% of starting body weight at the top dose vs roughly 13–15% for Wegovy (semaglutide). Tirzepatide also tends to control hunger more aggressively because it activates two gut hormones (GLP-1 and GIP) instead of one.

Wegovy still wins in three scenarios: you have a cardiovascular indication that's specifically labeled for semaglutide, your insurance covers it but not Zepbound, or you've had trouble tolerating dual-agonist medications in the past.

Both are weekly self-injections. Both require titration over 4–5 months. Both are now well stocked after the 2024–2025 shortages eased.

The SURMOUNT-1 trial put tirzepatide at 22.5% mean weight loss at 72 weeks on the 15 mg dose. STEP-1 put semaglutide at 14.9% mean weight loss at 68 weeks on the 2.4 mg dose. A direct comparison study (SURMOUNT-5, reported in 2025) confirmed tirzepatide led semaglutide by roughly 7 percentage points at 72 weeks.

Translation: if you weigh 220 lb, you can reasonably expect to lose 45–50 lb on Zepbound and 30–35 lb on Wegovy if you stay on the top dose for over a year. Real-world results are usually 20–30% lower than trial numbers because of dose interruptions, side-effect drop-offs, and lifestyle drift.

Both drugs cause GI side effects in the first 8–12 weeks: nausea, constipation, occasional vomiting, reflux, fatigue. The aggregate rate is similar (~70% of users report at least one GI symptom), but the character differs.

• Semaglutide: more persistent nausea, slower onset of appetite suppression
• Tirzepatide: sharper appetite drop in week 1–2, more constipation, more 'sulfur burps'

Serious adverse events (pancreatitis, gallbladder disease, severe dehydration) occur in well under 1% of users on both drugs. The black-box warning on medullary thyroid carcinoma applies to both classes and is based on rodent data — no human signal has emerged in a decade of use.

Cash list price is similar — about $1,350/mo for Wegovy and $1,060/mo for Zepbound at retail. Both manufacturers run a direct-pay program (NovoCare and LillyDirect) that drops cash pricing to roughly $499/mo for self-pay patients filling at participating pharmacies.

Insurance coverage is the more important variable. Wegovy is covered by ~45% of commercial plans; Zepbound by ~40%. Medicare and most Medicaid plans cover neither for weight loss as of early 2026, though both are commonly covered for type 2 diabetes (Ozempic and Mounjaro).

• You have established cardiovascular disease and want the SELECT-trial-backed indication
• Your insurance formulary covers Wegovy but not Zepbound
• You've previously tolerated semaglutide (Ozempic) without major side effects
• You prefer the longer real-world track record (FDA approved 2021 vs 2023 for Zepbound)

• You want the highest probability of >20% weight loss
• You also have moderate-to-severe sleep apnea (Zepbound now carries the OSA indication)
• Your insurance covers it, or you can swing the $499 LillyDirect cash price
• You did not get the appetite suppression you expected on semaglutide